						·		• •
	70-1445	922A2.149		AFTY. DOCEST NO. SPC92-02A2	SERIAL N	Sheet 1.0 0. 2,744	DE 7	·
INFORMATION DISCLOSURE CITATION IN AN APPLICATION				APPLICANT John Morley	1 00/30	2,744		
•	(Use several sheets if necessary)			FILING DATE February 2, 1995	GROUP 1206	· · ·		
		. • .	ַ ָ	.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL		DOCUMENT NUMBER.	DATE	NAMB	CLASS	SUB- CLASS	FILING D APPROPRI	
N	AA	3,341,593	9-12-67	Zeile et al.		·		***
i	AB	3,994,974	11-30-76	Murakami <u>et al</u> .	260	562A		
	AC	4,119,710	10-10-78	Englehardt et al.	424	282	· -	
	AD	3,885,047	5-20-75	Seidehamel <u>et al</u> .	424	330		
N	AE	3,985,897	10-12-76	Seidehamel <u>et al</u> .	-424	321		
•	AF		·					
•	AG	·						
•	АН		·					
	AI						· · · · · · · · · · · · · · · · · · ·	
	AJ							•
	AK.							
	·		FOR	EIGN PATENT DOCUMENTS		·		
W.			COUNTRY	CLASS	SUB- CLASS	Transl <i>i</i> Yes	NO NO	
	AL	2128258	11-AUG-83	Germany				
	AM	4014252	7-NOV-91	Germany				
	AN .	2662691 .	6-DEC-91	France (Derwent Abstract only)			•	
	AO	2187734	16-SEP-87	UK				
<u> </u>	AP	455155	26-APR-91	EPO				
V	AQ	93/00090	7-JAN-93	WO				
		OTHER DOCUMEN	rs' (Including	Author, Title, Date, Pertin	ent Page	s, Etc.)		
<i>\lambda</i>	AR	Murase, K. et al., "Absolute Configurations of Four Isomers of 3-Formamido-4-hydroxy- α [[N-p-methoxy- α -methylpenethyl)amino]methyl]benzyl] Alcohol, a Potent β -Adrenoreceptor Stimulant, "Chem. Pharm. Bull., $26(4)$:1123-1129 (1978).						
	AS .	Schill, G. et al., "Chiral Separations of Cationic and Anionic Drugs on an α_1 -Acid Glycoprotein-Bonded Stationary Phase (ENANTIOPAC®)," Journal of Chromotography, 365:73-88 (1986).						
6	AT	Hartley D. and Middlemiss D., "Absolute Configuration of the Optical Isomers of Salbutamol," <i>Journal of Medicinal Chemistry,</i> 14(9):895-896 (1971).						
EXAMIN	VER	Mooh.		DATE CONSIDERED \$14/05				

:

PURM PTO-1449 (REV. 7-80) ATTY. DOCKET NO. : SERIAL NO. SPC92-02A2 08/382,744 INFORMATION DISCLOSURE CITATION APPLICANT . IN AN APPLICATION John Morley (Use several sheets if necessary) PILING DATE GROUP ... February 2, 1995 1206 PATENT DOCUMENTS EXAM-SUB-CLASS PILING DATE DOCUMENT NUMBER DATE NAME CLASS INI-APPROPRIATE OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Borgström, L. et al., "Pharmacokinetic Evaluation in Man of AX Terbutaline Given as Separate Enantiomers and As the Racemate," Br. J. Clin Pharmac., 27:49-56 (1989). Koster, A. et al., "Stereoselective Formation of Fenoterol-Para-AY Glucuronide and Fenoterol- Meta-Glucuronide in Rat Hepatocytes and Enterocytes, Biochemical Pharmacology, 35(12):1981-1985 (1986).Tan, Y.K. and Soldin, S.J., "Analysis of Salbutamol Enantiomers AZin Human Urine by Chiral High-Performance Liquid Chromatography and Preliminary Studies Related to the Stereoselective Disposition Kinetics in Man, " J. Chromat., 422:187-195 (1987). Kaiser, G. et al., "Identification and Quantification of β -AR2 Adrenoceptor Sites in Red Blood cells from Rats," Naunyn-Schmiedeberg's Arch. Pharmacol., 305:41-50 (1978). Hawkins, C.J. and Klease, G.T., "Relative Potency of (-) and (\pm) -AS2 Salbutamol on Guinea Pig Tracheal Tissue, " Journal Medicinal Chemistry, 16(7):856-857 (1973). Brittain, R.T. et al., "Some Observations on the β -Adrenoceptor AT2 Agonist Properties of the Isomers of Salbutamol, " Br. J. Pharmac., 48:144-147 (1973). Buckner, C.K. and Abel, P., "Studies on the Effects of AU2 Enantiomers of Soterenol, Trimetoquinol and Salbutamol on BETA Adrenergic Receptors of Isolated Guinea-Pig Atria and Trachea," J. Pharmacol Exp. Therap., 189(3):616-625 (1974). Jeppsson, A.-B. and Waldeck, B., "Interaction Between Bambuterol AV2 and Physostigmine: Aspects on Cholinesterase Inhibition and Neuromuscular Transmission in the Smooth and Skeletal Muscles of the Guinea-Pig, Pharmac. and Tox., 63:211-214 (1988). DATE CONSIDERED EXAMINER

heet 4 of 7

	PORM PTO-1449. (REV. 7-80) INFORMATION DISCLOSURE CITATION			ATTY. DOCKST NO. SPC92-02A2	SERIAL NO				
1	IN AN APPLICATION (Use several sheets if necessary)				APPLICANT John Morley				
					FILING DATE February 2, 1995	GROUP 1206			
	U.S. PATENT DOCUMENTS								
BX DXI DXI TU	BR [-	·	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	PILING DATE IP APPROPRIATE	
		<u> </u>						•	
<u> </u>		<u> </u>			y			<u> </u>	
				-,	uthor, Title, Date, Pertine				
		AW2	Computer P	cini = Oni - Fo	r Publications Relatin	g-to-"1	'A-200 5	- u 	
V	\ _	AX2	AX2 Index Nominum for Fenoterol and Formoterol.						
·		AY2	USAN Cumulative List of References for Fenoterol and Formoterol (1961-1991).						
		AZ2	Package Insert for the Product Fenoterol as sold in Japan.						
		AR3	Merck Index 11th Edition, Item 9502-for Tretoquinol.						
		AS3	Fogleman, F. and Grundy, H.F., "A Comparison of the Cardiovascular Actions of AQ 110 With Those of Isoprenaline and Salbutamol," Br. J. Pharmac., 38:416-432 (1970).						
		AT3	Ahn, C-H. et al., "Characterization of the Inhibition of U46619-Mediated Human Platelet Activation by the Trimetoquinol Isomers," Biochemical Pharmacology, 37(15):3023-3033 (1988).						
		AU3	Computer Printout of Scrip No. 1678, pg. 31 (December 18, 1991).						
		AV3	Scrip No. 1686, pg. 12 (January 24, 1992).						
И		AW3	Patterson, American Re	J. W. et al view of Res	., "State of the Art B piratory Disease, 120:	ronchoo 1149-11	dilator 187 (19	Drugs," 79).	
EXA	IIN	ER	looh		DATE CONSIDERED W/4/05	<u>.</u>		·	

<u>/</u>			<u> </u>		eet 7	o£ 7	
FORM PTO-1449 (REV. 7-80) INFORMATION DISCLOSURE CITATION IN AN APPLICATION			TATION	ATTY. DOCKET NO. SPC92-02A2	08/38). 2,744	
				APPLICANT John Morley			
	(Use several sheets if necessary)			FILING DATE February 2, 1995	1206	•	
			ຫ.s	. PATENT DOCUMENTS		,	
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS .	SUB- CLASS	PILING DATE IP APPROPRIATE
							ač.
					<u> </u>		
	,	OTHER DOCUMENT	S (Including A	Author, Title, Date, Pertine	ent Pages	, Etc.)	
N	AZ5			ifen and Terbutaline i y, 104:205-206 (1981)		caria, ⁿ	British
	AR6	Regulation	of Beta-Ad	n Prevents Terbutaline renoceptors in Guinea rch Communications, 19	Pig Lur	ig," Bi	ochemical
V	AS6	Mazzoni, L and Isopre	. et al., ". naline," Br	An Anomalous Interacti . <i>J. Pharm., 91</i> :526 (1	on Betw .987).	veen Pro	opranolol
			:	-	•		
			•				
·		٠.		*			,
						-	
-			•				
	_						
EXAMIN	er //	Looh		DATE CONSIDERED W/14/05			

DOC.	ID NO	SPC922A2		(Sb	eet 1 of 1
	7-80)			ATTY: DOCKST NO. SPC92-02A2	V3/38	o. 2,744	
	INFOR	MATION DISCLOS IN AN APPLICA		APPLICANT John Morley	·		
		(Use several sheets if neces	(ary) .	FILING DATE February 2, 1995	GROUP		1.
		· · · · · · · · · · · · · · · · · · ·	. n	S. PATENT DOCUMENTS	1206	•	
BXAM		T	1	TATALL BOCCHANTS	·	SUB-	FILING DATE IF
INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	CLASS	APPROPRIATE
~	AF.	5,362,755	11-8-94	Barberich et al.	514	649.	12-7-93
			•				
		·					
• •			•				
				i i			
			· .				
					·		
				·			
			FORE	IGN PATENT DOCUMENTS			
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
•		<u>.</u>					
					·		1
				·		·	
		OTHER DOCUMENTS	(Including	Author, Title, Date,	Pertinent Page	es, Etc.)
1	AT6	Morley, J., adrenocepto 3:228-233	r Agonists	Viewpoint: Untowar in Asthma," <i>Europ</i>	d Effects c ean Respira	f Beta	- ournal,
					·		
						·	
EXAMI	NER	Mooh	·	DATE CONSIDERED	14/65		· .